SI3630112T1 - Kombinacija regorafeniba in nivolumaba za zdravljenje raka - Google Patents

Kombinacija regorafeniba in nivolumaba za zdravljenje raka

Info

Publication number
SI3630112T1
SI3630112T1 SI201831091T SI201831091T SI3630112T1 SI 3630112 T1 SI3630112 T1 SI 3630112T1 SI 201831091 T SI201831091 T SI 201831091T SI 201831091 T SI201831091 T SI 201831091T SI 3630112 T1 SI3630112 T1 SI 3630112T1
Authority
SI
Slovenia
Prior art keywords
regorafenib
nivolumab
combination
treating cancer
cancer
Prior art date
Application number
SI201831091T
Other languages
English (en)
Slovenian (sl)
Inventor
Sabine Hoff
Lars Rose
Dieter Zopf
Fabian Kiessling
Wiltrud Lederle
Dennis Doleschel
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SI3630112T1 publication Critical patent/SI3630112T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201831091T 2017-06-02 2018-05-25 Kombinacija regorafeniba in nivolumaba za zdravljenje raka SI3630112T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
EP18725258.0A EP3630112B9 (en) 2017-06-02 2018-05-25 Combination of regorafenib and nivolumab for treating cancer
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
SI3630112T1 true SI3630112T1 (sl) 2024-06-28

Family

ID=58992733

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201831091T SI3630112T1 (sl) 2017-06-02 2018-05-25 Kombinacija regorafeniba in nivolumaba za zdravljenje raka

Country Status (22)

Country Link
US (4) US11951166B2 (enExample)
EP (2) EP3630112B9 (enExample)
JP (3) JP7303122B2 (enExample)
KR (2) KR102843438B1 (enExample)
CN (3) CN117899212A (enExample)
AU (2) AU2018276273B2 (enExample)
BR (1) BR112019025478A8 (enExample)
CA (2) CA3244313A1 (enExample)
DK (1) DK3630112T3 (enExample)
ES (1) ES2978337T3 (enExample)
FI (1) FI3630112T3 (enExample)
HR (1) HRP20240551T1 (enExample)
HU (1) HUE066487T2 (enExample)
IL (2) IL317015A (enExample)
LT (1) LT3630112T (enExample)
MX (1) MX2023001721A (enExample)
PE (2) PE20200859A1 (enExample)
PL (1) PL3630112T3 (enExample)
PT (1) PT3630112T (enExample)
RS (1) RS65488B9 (enExample)
SI (1) SI3630112T1 (enExample)
WO (1) WO2018219807A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3630112T (pt) * 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
TW202539722A (zh) * 2023-12-01 2025-10-16 耶魯大學 治療癌症的組合物和方法
WO2026024670A1 (en) * 2024-07-23 2026-01-29 Lantern Pharma Inc. Treating triple negative breast cancer (tnbc) with combinations of immunotherapy and acylfulvenes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
JP2009514921A (ja) 2005-11-10 2009-04-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト 糖尿病性神経障害を処置するためのジアリールウレア
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
HRP20181462T1 (hr) * 2012-09-25 2018-11-02 Bayer Pharma Aktiengesellschaft Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
US10570202B2 (en) * 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
US20170165364A1 (en) 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
JP6626085B2 (ja) 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
SG10202005315SA (en) * 2014-08-19 2020-07-29 Nat Univ Corporation Okayama Univ Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
KR20170080697A (ko) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
EP3463456A1 (en) 2016-06-03 2019-04-10 ImClone LLC Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
PT3630112T (pt) * 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
US10995149B2 (en) * 2017-06-05 2021-05-04 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use

Also Published As

Publication number Publication date
EP3630112B1 (en) 2024-01-31
CN117582495A (zh) 2024-02-23
IL270948A (en) 2020-01-30
KR102843438B1 (ko) 2025-08-06
US20200188372A1 (en) 2020-06-18
CN110662540A (zh) 2020-01-07
AU2018276273A1 (en) 2019-12-12
RU2019143599A3 (enExample) 2021-09-10
US11517622B2 (en) 2022-12-06
IL270948B2 (en) 2025-07-01
EP4342542A3 (en) 2024-06-05
EP4342542A2 (en) 2024-03-27
HRP20240551T1 (hr) 2024-07-05
JP2022169780A (ja) 2022-11-09
KR20200011971A (ko) 2020-02-04
MX2023001721A (es) 2023-02-22
FI3630112T3 (fi) 2024-05-02
JP7303122B2 (ja) 2023-07-04
JP2024096905A (ja) 2024-07-17
RU2019143599A (ru) 2021-07-09
AU2023282197B2 (en) 2025-06-26
CN110662540B (zh) 2024-01-26
JP7806119B2 (ja) 2026-01-26
PT3630112T (pt) 2024-04-23
ES2978337T3 (es) 2024-09-10
HUE066487T2 (hu) 2024-08-28
AU2023282197A1 (en) 2024-01-04
BR112019025478A8 (pt) 2022-12-06
PE20242220A1 (es) 2024-11-19
DK3630112T3 (da) 2024-04-22
US20200179354A1 (en) 2020-06-11
KR102673422B1 (ko) 2024-06-07
US20220133888A1 (en) 2022-05-05
CN117899212A (zh) 2024-04-19
RS65488B9 (sr) 2024-09-30
EP3630112A1 (en) 2020-04-08
PE20200859A1 (es) 2020-08-25
IL317015A (en) 2025-01-01
EP3630112B9 (en) 2024-06-26
CA3065125A1 (en) 2018-12-06
BR112019025478A2 (pt) 2020-06-23
WO2018219807A1 (en) 2018-12-06
US11951166B2 (en) 2024-04-09
PL3630112T3 (pl) 2024-07-01
LT3630112T (lt) 2024-05-10
KR20240091188A (ko) 2024-06-21
JP7475402B2 (ja) 2024-04-26
IL270948B1 (en) 2025-03-01
CA3244313A1 (en) 2025-06-13
CA3065125C (en) 2025-06-10
AU2018276273B2 (en) 2023-12-21
RS65488B1 (sr) 2024-05-31
JP2020521786A (ja) 2020-07-27
US20200155674A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
IL267247B (en) Compositions and methods for treating cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
IL276808A (en) Preparations and methods for the treatment of cancer
IL258955B2 (en) Cancer treatment preparations and methods
IL274837A (en) Methods and preparations for the treatment of cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
SMT202000053T1 (it) Trattamento combinato del cancro
IL325803A (en) Compositions and methods for treating cancer
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL276203A (en) Compounds and methods for treating cancer
HUE066487T2 (hu) Regorafenib és nivolumab kombinációja rák kezelésére
IL272782A (en) Preparations and methods for the treatment of cancer
IL267613A (en) Pancreatic cancer treatment
SG11202005163PA (en) Methods of treating cancer
IL255169A0 (en) Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer
IL274748A (en) Improved cancer treatment
IL269123A (en) Methods of treating cancer
SG11202000724XA (en) Methods and compositions for the treatment of cancer
IL280262A (en) Compositions and methods for treating cancer
ZA201904626B (en) Cancer treatment method and composition
IL274866A (en) Preparations and methods for the treatment of cancer
ZA201805595B (en) Treatment of skin cancer